Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Current Pharmaceutical Design
Title:Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Volume: 19 Issue: 32
Author(s): Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Export Options
About this article
Cite this article as:
Christakou Charikleia and Diamanti-Kandarakis Evanthia, Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320011
DOI https://dx.doi.org/10.2174/1381612811319320011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Familial Hypercholesterolemia: Update and Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant and Antimicrobial Activities of Cinnamic Acid Derivatives
Mini-Reviews in Medicinal Chemistry Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Application of Spray-drying and Electrospraying/Electospinning for Poorly Watersoluble Drugs: A Particle Engineering Approach
Current Pharmaceutical Design Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology The Use of Thiazides in Chronic Kidney Disease
Current Hypertension Reviews Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Psoriasis in Children: A Review
Current Pediatric Reviews Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Nanoparticulated Quercetin in Combating Age Related Cerebral Oxidative Injury
Current Aging Science Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry